Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

619 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Human immunodeficiency virus type 1 primary isolate neutralization resistance is associated with the syncytium-inducing phenotype and lower CD4 cell counts in subtype CRF01_AE-infected patients.
Polonis VR, de Souza MS, Darden JM, Chantakulkij S, Chuenchitra T, Nitayaphan S, Brown AE, Robb ML, Birx DL. Polonis VR, et al. Among authors: brown ae. J Virol. 2003 Aug;77(15):8570-6. doi: 10.1128/jvi.77.15.8570-8576.2003. J Virol. 2003. PMID: 12857927 Free PMC article.
Heterosexually acquired CRF01_AE/B recombinant HIV type 1 found in Thailand.
Viputtijul K, de Souza M, Trichavaroj R, Carr JK, Tovanabutra S, McCutchan FE, Sriplienchan S, Buapunth P, Chuenchitra C, McNeil JG, Birx DL, Brown AE, Nitayaphan S. Viputtijul K, et al. Among authors: brown ae. AIDS Res Hum Retroviruses. 2002 Nov 1;18(16):1235-7. doi: 10.1089/08892220260387986. AIDS Res Hum Retroviruses. 2002. PMID: 12494923
Specific antibody responses to vaccination with bivalent CM235/SF2 gp120: detection of homologous and heterologous neutralizing antibody to subtype E (CRF01.AE) HIV type 1.
Kim JH, Pitisuttithum P, Kamboonruang C, Chuenchitra T, Mascola J, Frankel SS, DeSouza MS, Polonis V, McLinden R, Sambor A, Brown AE, Phonrat B, Rungruengthanakit K, Duliege AM, Robb ML, McNeil J, Birx DL; Thai AIDS Vaccine Evaluation Group. Kim JH, et al. Among authors: brown ae. AIDS Res Hum Retroviruses. 2003 Sep;19(9):807-16. doi: 10.1089/088922203769232601. AIDS Res Hum Retroviruses. 2003. PMID: 14585211 Clinical Trial.
The Thai phase III trial (RV144) vaccine regimen induces T cell responses that preferentially target epitopes within the V2 region of HIV-1 envelope.
de Souza MS, Ratto-Kim S, Chuenarom W, Schuetz A, Chantakulkij S, Nuntapinit B, Valencia-Micolta A, Thelian D, Nitayaphan S, Pitisuttithum P, Paris RM, Kaewkungwal J, Michael NL, Rerks-Ngarm S, Mathieson B, Marovich M, Currier JR, Kim JH; Ministry of Public Health–Thai AIDS Vaccine Evaluation Group Collaborators. de Souza MS, et al. J Immunol. 2012 May 15;188(10):5166-76. doi: 10.4049/jimmunol.1102756. Epub 2012 Apr 23. J Immunol. 2012. PMID: 22529301 Free PMC article. Clinical Trial.
Safety and immunogenicity of combinations of recombinant subtype E and B human immunodeficiency virus type 1 envelope glycoprotein 120 vaccines in healthy Thai adults.
Pitisuttithum P, Nitayaphan S, Thongcharoen P, Khamboonruang C, Kim J, de Souza M, Chuenchitra T, Garner RP, Thapinta D, Polonis V, Ratto-Kim S, Chanbancherd P, Chiu J, Birx DL, Duliege AM, McNeil JG, Brown AE; Thai AIDS Vaccine Evaluation Group. Pitisuttithum P, et al. Among authors: brown ae. J Infect Dis. 2003 Jul 15;188(2):219-27. doi: 10.1086/376506. Epub 2003 Jul 3. J Infect Dis. 2003. PMID: 12854076 Clinical Trial.
619 results